OT re IDPH (news just released)
EU panel backs cancer drug from Schering, Idec
September 25, 2003 1:27:00 PM ET
LONDON, Sept 25 (Reuters) - A new cancer treatment from German drugmaker Schering AG was recommended for approval by a European panel of experts on Thursday.
The Committee for Proprietary Medicinal Products gave a positive opinion on Zevalin, a treatment for non-Hodgkin's lymphoma which Schering licensed from Idec Pharma (IDPH), at its monthly meeting, the London-based European Medicines Evaluation Agency said.
CPMP recommendations for marketing approval are normally endorsed by the European Commission within 90 days. REUTERS
© 2003 Reuters
Market Data 
Markets 
AI
